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PENILAIAN FARMAKOEPIDEMIOLOGIKAL UNTUK PENGAWALAN 
GLISEMIK DI KALANGAN PESAKIT DIABETES YANG MENERIMA 
PELBAGAI REGIMEN DI HOSPITAL PULAU PINANG 
 
ABSTRAK 
  
Secara umum, penyakit diabetes mellitus jenis 2 tidak boleh dirawat dengan 
menggunakan satu jenis drug atau dengan cara mengubah gaya hidup sahaja. Tambahan 
agen antidiabetes atau peningkatan dos disarankan untuk mengawal keadaan penyakit 
tersebut daripada menjadi bertambah teruk. Tujuan kajian ini dijalankan adalah untuk 
menilai drug antidiabetes yang digunakan di Hospital Pulau Pinang dan hubungannya 
dengan dapatan klinikal rawatan penyakit. Juga untuk menentukan bilangan pesakit 
diabetes yang boleh mencapai sasaran klinikal yang ditetapkan. Hubungkait di antara 
tempoh masa seseorang pesakit menghidap diabetes dengan strategi rawatan, bilangan 
komplikasi lain yang dihidapi, komorbiditi dan dapatan klinikal juga turut dinilai. Kajian 
ini merupakan kajian pemerhatian retrospektif keratan silang melibatkan 1014 pesakit 
diabetes mellitus jenis 2 yang menghadiri klinik diabetes pesakit luar di hospital 
berkenaan. Kajian ini turut meneliti rekod perubatan setiap pesakit bermula pada tahun 
2005 hingga 2007. Dapatan klinikal secara primer dan sekunder untuk rawatan diabetes 
yang disarankan untuk pemantauan termasuklah plasma glukosa sewaktu berpuasa, 
HbA1c, tekanan darah (BP) dan profil lipid. Data yang diperolehi dikumpul dan 
dianalisa menggunakan pakej perisian SPSS versi 15.0 ( SPSS Inc., chicago, IL) dan 
Microsoft Excel. 54% daripada jumlah pesakit adalah wanita dan 54.1% daripadanya 
xix 
 
adalah kaum Cina. Hasil kajian mendapati terdapat perbezaan secara signifikan dalam 
kawalan glisemik bagi beberapa strategi rawatan yang digunakan. Pesakit yang 
menerima rawatan mono agen hipoglisemik oral (OHA) mempunyai tahap HbA1c yang 
paling rendah. Walaupun penambahbaikan rawatan sama ada melalui penambahan agen 
antidiabetes atau peningkatan dos dilaksanakan, didapati paras glukos di kalangan 
pesakit masih tinggi (p<0.001). Hampir separuh daripada pesakit diabetes yang 
menjalani terapi mono OHA tidak mengalami sebarang komplikasi. Sebaliknya, majoriti 
(92.8%) daripada pesakit diabetes tidak terkawal mengalami komplikasi walaupun 
mereka mengikuti pengubatan antidiabetes. Terdapat hubungan di antara tempoh 
diabetes dengan strategi rawatan, bilangan komplikasi dan komorbiditi (p<0.001). 
Berdasarkan keputusan kajian yang diperolehi, rumusan telah dibuat iaitu terapi mono 
menggunakan OHA memberikan dapatan klinikal yang lebih baik berbanding regimen 
rawatan lain. Lebih daripada separuh pesakit yang menerima terapi mono OHA 
mempunyai jangka masa rawatan yang lebih pendek. Perbezaan ini tidak semestinya 
menggambarkan kegagalan regimen rawatan seperti yang disarankan dalam Garis 
Panduan Amalan Klinikal Malaysia. Hal ini mungkin disebabkan oleh keadaan penyakit 
yang bertambah teruk dan masalah komplians pesakit terhadap pengambilan ubat 
antidiabetes. Kajian ini akan memberikan input kepada Kementerian Kesihatan Malaysia 
dalam mengambil langkah perlu untuk meningkatkan kualiti hidup pesakit diabetes.  
 
 
Kata kunci: OHA, diabetes jenis 2, kawalan glisemik, tempoh penyakit, komorbiditi, 
komplikasi 
xx 
 
A PHARMACOEPIDEMIOLOGICAL  EVALUATION OF GLYCAEMIC 
CONTROL AMONG DIABETES PATIENTS RECEIVING DIFFERENT 
TREATMENT REGIMENS AT PENANG GENERAL HOSPITAL 
 
ABSTRACT 
Generally, type 2 diabetes mellitus cannot be managed with a single drug or 
lifestyle changes alone; therefore, adding anti-diabetic agents or increasing the dose is 
recommended to control the disease progression. This study aimed to evaluate the anti-
diabetic drugs used at Penang General Hospital in relation to the clinical outcomes of the 
disease management and to determine the proportions of diabetic patients who achieved 
the target levels. The association between diabetes duration and each of: treatment 
strategies, number of complications, comorbidities and clinical outcomes was also 
evaluated. This was a cross-sectional retrospective observational study involving 1014 
patients with type 2 diabetes mellitus who attended the outpatient diabetes clinic at the 
Penang General Hospital in Malaysia. Each patient’s medical record from 2005 to 2007 
was reviewed. The primary and secondary clinical outcomes for treatment of diabetes 
that are recommended to be monitored include fasting plasma glucose, haemoglobin 
A1c (HbA1c), blood pressure (BP) and the lipid profile. All the collected data were 
analysed using the SPSS (version 15.0) software package (SPSS Inc., Chicago, IL) and 
Microsoft Excel. Female patients constituted 54% of the study population, and 54.1% of 
the sample was Chinese. There were significant differences in glycaemic control 
between the treatment strategies, and patients receiving monotherapy with oral 
xxi 
 
hypoglycaemic agents (OHA) had the lowest HbA1c level. Furthermore, high glucose 
levels were observed in spite of the treatment intensification either by addition of anti-
diabetic agents or increment of the drug dose (p <0.001). About half of the diabetic 
patients who were on monotherapy with OHAs had no complications. A large proportion 
(92.8%) of the study population had uncontrolled diabetes even though they were 
receiving anti-diabetic medications. There was an association between the diabetes 
duration and each of the following: treatment strategies, number of complications, and 
co-morbidities (p <0.001). On the basis of these results, we conclude that monotherapy 
with OHAs therapy had better outcomes (glycaemic control, BP, high density 
lipoprotein cholesterol, and the number of complications) than the other treatment 
regimens. Moreover, more than half of those who were on monotherapy with OHA 
therapy had relatively shorter treatment period. The differences observed in the study 
outcomes may not necessarily reflect the failure of the other treatment modalities 
recommended by the Malaysian Clinical Practice Guidelines. Rather, these findings 
could be due to the progression of the disease and possibly inadequate patient 
compliance to the anti-diabetic medications. These findings provide an input to the 
Malaysian Ministry of Health to take steps for improving the management and quality of 
life of patients with type 2 diabetes. 
Keywords: OHAs, type 2 diabetes, glycaemic control, disease duration, co-morbidities, 
complications. 
 
 
CHAPTER 1 
INTRODUCTION 
 
This study attempts to evaluate the medications used for the treatment of type 
2 diabetes and the clinical outcomes achieved at Penang General Hospital, Malaysia. 
This chapter indicates the problem of uncontrolled diabetes in spite of the patients 
taking anti-diabetic medications. It also contains the research questions, and the 
study objectives which have been investigated. 
 
1.1 Introduction 
Diabetes mellitus is a costly disease for both the diabetic patient and the 
healthcare sector, because of the severity and chronic nature of its complications 
(Ooyub et al., 2004). On the other hand, many studies including the United Kingdom 
Prospective Diabetes Study (UKPDS) have reported a significant reduction in 
microvascular complications associated with tight glycaemic control (Stratton et al., 
2000). On the other hand, the effect of the glycaemic control on the macrovascular 
complications is incompletely understood (American Diabetes Association, 2002). 
Guidelines for the management of type 2 diabetes mellitus outline many treatment 
strategies depending on the HbA1c level, starting by the diet therapy which is 
intensified by initiating pharmacotherapy (Ministry of Health Malaysia et al., 2004; 
Rodbard et al., 2007). 
 
Pharmacological treatment of diabetes mellitus type 2 begins with an oral 
agent, usually metformin or sulfonylurea (SU). If proper glycaemic control is not 
achieved with a single drug, the combination of these two drugs is recommended 
1 
 
(American Diabetes Association, 2008c; Edwards et al., 2008). Over time, most 
diabetic patients will require three or more oral anti-diabetic medications, and they 
may even have to use insulin. Although the American Diabetes Association (ADA) 
recommends metformin for the initiation of monotherapy, there are no guidelines to 
help physicians select the second or third drug, if additional medication is required 
(American Diabetes Association, 2008c). Guidelines from the American College of 
Endocrinology (ACE) and American Association of Clinical Endocrinologists 
(AACE) recommend several therapy options, depending on the patient's HbA1c level 
(American College of Endocrinology and American Association of Clinical 
Endocrinologists, 2002). Similarly, Malaysian guidelines recommend the treatment 
strategies depending on the screening of the HbA1c level. Moreover, modification of 
the treatment regimen would be recommended if the current regimen failed to 
achieve the target level (Ministry of Health Malaysia et al., 2004).  
 
1.2 Problem Statement 
Diabetes mellitus is becoming a worldwide epidemic (World Health 
Organization, 2000). Epidemiologists estimate that by 2025 diabetes will affect 300 
million people (King et al., 1998), with about half of them from the Asia Oceania 
region alone. During this time, there will be three-fold increase of this disease in 
Asia, both in developed countries like China and India, and in the rapidly developing 
countries, such as Malaysia and Singapore (King et al., 1998). In the last two 
decades, Malaysia has undergone rapid growth, registering an improved quality of 
life, a reduced mortality rate, and an increased median age. Unfortunately, this great 
progress also makes Malaysia highly prone to the diabetes epidemic (Yun et al., 
2007).  
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In order to properly manage the disease, patients with diabetes must comply 
with both dietary and pharmacologic therapy. Furthermore, given the chronic and 
costly nature of diabetes, it is important to know the best treatment strategy that leads 
to the best glycaemic control, i.e., the most dramatic reduction in HbA1c level. As 
the oral hypoglycaemic agents (OHAs) have limited range of HbA1c reduction, the 
combination of OHAs or concurrent therapy of OHAs with insulin is recommended 
to reduce the HbA1c level as far as possible (Kuritzky, 2006). The majority of type 2 
diabetic patients, start bed time insulin because of the high morning fasting glucose 
levels, which related to the excessive glucose production overnight. Some elderly 
patients who have the higher levels during the afternoon may have better response to 
the morning insulin (Cutfield, 2009). The tight control will prevent or reduce the 
incidence of macrovascular and microvascular complications, thereby decreasing the 
burden on both the patients and the healthcare sector (Beck-Nielsen and Henriksen, 
2007; Mathieu, 2009). The ratio of the diabetic patients who can achieve the target 
glycaemic control is varied from one population to another. This depends on many 
factors; the treatment and the patients compliance to the treatment are part of these 
factors. In Malaysia, there is a high proportion of patients with uncontrolled diabetes 
despite taking anti-diabetic therapy (Ismail et al., 2000; Eid et al., 2004; Sulaiman et 
al., 2004; Mafauzy, 2006; Tan et al., 2008). Two studies conducted elsewhere (Japan 
and the U.S) reported that the proportions of patients with good glycaemic control 
were more than those with poor glycaemic control (Kobayashi et al., 2006; Wahba 
and Chang, 2007).    
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1.3 Research Questions  
i. Are there any differences in the clinical outcomes (glycaemic control, blood 
pressure (BP), and lipid profile) achieved by the type 2 diabetic patients on 
different pharmacological regimens? 
ii. Do complications and co-morbidities have effects on the clinical outcomes 
(glycaemic control, BP and the lipid profile) of the type 2 diabetic patients? 
iii. Is there any association between the diabetes duration and each of the 
following: pharmacological treatment regimen, number of complications, and 
co-morbidities? 
iv. Is there any difference in the glycaemic control achieved by patients on 
different doses of anti-diabetic agents? 
 
1.4 Rationale of the Study 
Given that each anti-diabetic agent can lower HbA1c levels to some extent, 
we must determine the best way to utilise these drugs to optimise their effects in 
treating diabetes. Three years after the diagnosis of diabetes, 50% of diabetic patients 
need more than one therapeutic agent to achieve sufficient glycaemic control. By 
nine years after diagnosis, 75% of diabetic patients will require multiple therapies to 
properly control their glucose levels (Turner et al., 1999). Since patients on both SU 
and metformin monotherapy experience a deterioration of glycaemic control over 
time, β-cell failure may be a fundamental characteristic of type 2 diabetes and not the 
result of a specific therapy failure (Kimmel and Inzucchi, 2005). This statement may 
only be valid if the patient is compliant to the drug therapy.  
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ADA recommends metformin as the first-line treatment for type 2 diabetes 
(American Diabetes Association, 2008c). Also it recommends the use of additional 
agents including insulin, if the target glycaemic control is not achieved with 
metformin therapy. Early initiation of insulin therapy is recommended for patients 
who are losing weight or have severe hyperglycaemic signs (American Diabetes 
Association, 2008c). The consensus algorithm for the medical management of type 2 
diabetes regarding the second medication added to metformin was to choose either 
insulin or SU. The HbA1c level will help to determine which agent is selected next 
(American Diabetes Association, 2008c; Nathan et al., 2009). Also, the ADA 
cautioned against the use of thiazolidinediones (TZD), and did not include other 
medications (pramlintide, exantide, α-glucosidase inhibitors, glinides and dipeptidyl 
peptidase IV inhibitors) in its consensus algorithm due to their relatively lower 
efficacy (American Diabetes Association, 2008c). The AACE gave examples of 
treatment regimens for type 2 diabetes, and SU were their first choice in combination 
with metformin when HbA1c levels are 6%-7% (Rodbard et al., 2007). Optimal 
second- and third-line therapies, as well as the best combinations of oral anti-diabetic 
agents (both with or without insulin therapy) must be identified in order to attain the 
desired glycaemic control in diabetic patients. To our knowledge, studies that 
investigated anti-diabetic therapies and glycaemic control among type 2 diabetes 
mellitus patients in Malaysia are very limited. This study aimed to evaluate the use of 
anti-diabetic therapies and to determine the level of glycaemic control in Malaysian 
type 2 diabetes mellitus patients. 
 
 
 
5 
 
1.5 Objectives of the Study 
 The main objective of this study was to evaluate the anti-diabetic medication 
regimens (including OHAs monotherapy, multiple OHAs, OHAs with insulin and 
insulin monotherapy) used at Penang General Hospital in relation to the clinical 
outcomes. The clinical parameters focused on include fasting plasma glucose (FPG), 
HbA1c, systolic BP, diastolic BP, high density lipoprotein (HDL) cholesterol, low 
density lipoprotein (LDL) cholesterol, triglycerides (TG) and total cholesterol.  
Other specific objectives of the study are: 
i. To evaluate the patient- and disease-related characteristics in relation to the 
glycaemic control. 
ii. To determine the proportion of diabetic patients who achieved the target 
glycaemic control. 
iii. To investigate the association between diabetes duration and each of the 
following: treatment strategies, number of complications and co-morbidities. 
iv. To evaluate the incidence of diabetes related complications, diabetes co-
morbidities, and changes in lipid profile and BP. 
v. To determine the relationship between the changes of dose regimen of the 
anti-diabetic medications and the glycaemic control. 
 
1.6 Significance of the Study 
i. This study has an important implication for the Malaysian population not just 
with regard to the high prevalence of type 2 diabetes mellitus, but also with 
regard to the large number of patients with uncontrolled diabetes. These 
conditions will require the Ministry of Health in Malaysia to create many 
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programmes to guide diabetic patients to improve the management of the 
disease and quality of life.  
ii. Physicians need to optimize drug therapy earlier in order to improve 
glycaemic control and delay the onset of diabetic complications. 
iii. Uncontrolled diabetes may not necessarily be attributed to the progression of 
the disease or the failure of the treatment strategy; rather it may be due to the 
patients’ non-compliance to drug therapy.  
 
1.7 The Scope of the Study 
This study focused on evaluation of type 2 diabetic patients who attended an 
out-patients clinic at Penang General Hospital, Malaysia. 
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CHAPTER 2 
LITERATURE REVIEW 
 
This chapter aims to review the relevant literature related to the types of 
diabetes mellitus, its signs and symptoms, diagnostic investigations, screening tests, 
diabetes prevalence and economic burden, and the strategies used in the management 
of the disease. 
 
2.1 Background 
Diabetes is a group of metabolic disorders characterized by an elevation in 
the blood glucose level that results from a deficiency in insulin production, insulin 
action, or both (Wild et al., 2000; Centers for Disease Control and Prevention, 2007).  
Diabetes mellitus is considered a growing health problem, with patients experiencing 
a high incidence of morbidity, premature mortality, and disability. Furthermore, 
complications of the disease lead to a considerable amount of lost productivity, as 
well as an increased demand on the health care system (Ooyub et al., 2004; Yun et 
al., 2007). Although Type 2 diabetes likely results from an interaction between 
genetic predisposition, behavioural risk, and environmental risk (Qvist et al., 2008; 
Brill, 2009). 
 
Type 2 diabetes is one of the most common chronic diseases, and is 
associated with other health conditions, such as obesity, hypertension, cardiovascular 
disease (CVD), and hyperlipidaemia (American Diabetes Association, 2008a). The 
increase in the prevalence of type 2 diabetes is associated with the worsening obesity 
epidemic, as 90% of type 2 diabetic patients possess excess weight (Hossain et al., 
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2007; American Diabetes Association, 2008a). Diabetes mellitus, which is 
accompanied by abnormalities in carbohydrate, fat, and protein metabolism, can 
cause acute health problems, such as hypoglycaemia and hyperglycaemia (American 
Diabetes Association, 2008a). Chronically, diabetes mellitus can cause both 
microvascular disease, including retinopathy, nephropathy, and neuropathy, as well 
as macrovascular diseases, such as ischemic heart disease, stroke, and peripheral 
vascular disease (American Diabetes Association, 2008a). All complications of 
diabetes lead to increased morbidity and premature mortality (Ministry of Health 
Malaysia et al., 2004; Centers for Disease Control and Prevention, 2007). 
 
2.2 Types of Diabetes 
The ADA issued diagnostic and classification criteria in 1997, and 
modifications were made in 2003 regarding the diagnosis of impaired fasting glucose 
(IFG) (American Diabetes Association, 2008c).  Diabetes mellitus includes four 
possible clinical classes as defined below. 
 
2.2.1 Type 1 Diabetes  
 It was previously called insulin-dependent diabetes mellitus (IDDM) or juvenile-
onset diabetes. Type 1 diabetes is described by an absolute insulin deficiency due to 
the destruction of β-cells by the body’s immune system. This type of diabetes usually 
strikes children and young adults, although onset of the disease can occur at any age. 
Diabetes mellitus type 1 in adults represents 5% to 10% of all diagnosed cases of 
diabetes (Centers for Disease Control and Prevention, 2007; American Diabetes 
Association, 2008c; American Diabetes Association, 2008a). 
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2.2.2 Type 2 Diabetes  
It was previously called non-insulin-dependent diabetes mellitus (NIDDM) or 
adult onset diabetes. Type 2 diabetes is the result of improper insulin utilization by 
cells, either through a progressive insulin secretory defect or through the 
development of insulin resistance. Type 2 diabetes mellitus usually presents in older 
adults, although some children and adolescents have been diagnosed as well. 
Diabetes mellitus type 2 in adults represents 90% to 95% of the diagnosed cases of 
diabetes (Wild et al., 2000; Centers for Disease Control and Prevention, 2007; 
American Diabetes Association, 2008a). As obesity contributes to the development 
of insulin resistance, most type 2 diabetic patients are obese (American Diabetes 
Association, 2008a).  
 
2.2.3 Gestational Diabetes Mellitus (GDM) 
A form of glucose intolerance that develops during pregnancy, GDM, requires 
treatment to normalize maternal blood glucose in order to avoid complications in the 
infant. After pregnancy, 5% to 10% of women with GDM are found to have diabetes 
mellitus, most likely type 2 diabetes. Women with a previous history of GDM have a 
40% to 60% chance of developing diabetes in the next 5-10 years (Centers for 
Disease Control and Prevention, 2007; Rodbard et al., 2007; American Diabetes 
Association, 2008a).  
 
2.2.4 Other Specific Types 
Other types of diabetes are due to genetic defects in β-cells function, genetic 
defects in the activity of insulin, diseases of the pancreas gland, and drugs or 
chemicals, including Human Immunodeficiency Virus (HIV) treatment or 
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immunosuppressants (Wild et al., 2000; Triplitt et al., 2005; American Diabetes 
Association, 2008c). 
 
2.3 Pre-diabetes 
 Pre-diabetes refers to blood glucose levels that are higher than normal, but 
not elevated enough to be classified as diabetes. Patients with pre-diabetes have an 
increased risk of developing type 2 diabetes, heart disease, and stroke. Pre-diabetes is 
categorized as either IFG or impaired glucose tolerance (IGT), depending on the test 
used for identification: FPG test or the 75-g oral glucose tolerance test (OGTT) 
(World Health Organization Consultation, 1999; Zhang et al., 2005; Grundy, 2006; 
Centers for Disease Control and Prevention, 2007; American Diabetes Association, 
2008a).  
 
2.4 Diagnosis, Screening, and Monitoring of Diabetes Mellitus 
The ADA recommends using FPG test to diagnose diabetes in non-pregnant 
adults and children. Although the 75-g OGTT is more sensitive and specific than the 
FPG in diagnosing diabetes, it is also more difficult and cosier to use in practice 
(Gabir et al., 2000; Rodbard et al., 2007; American Diabetes Association, 2008c). 
However, the OGTT is used to screen pregnant women with a risk of developing 
diabetes (American Diabetes Association, 2008c; American Diabetes Association, 
2008a). The HbA1c test is not recommended for the diagnosis of diabetes mellitus 
(American Diabetes Association, 2008a). However, this test reflects average blood 
sugar over several months and has a strong predictive value for future diabetic 
complications. Therefore, HbA1c should be used to monitor diabetic patients 
(Edelman et al., 2004; American Diabetes Association, 2008c).  
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2.5 Testing for Pre-diabetes and Diabetes in Asymptomatic Adults  
Type 2 diabetes has long presymptomatic phase until the patient is 
diagnosed. Testing is considered in patients with high risk including overweight 
(body mass index (BMI) 25-29.9 kg / m2) and obesity (BMI ≥30 kg / m2) (Colman 
et al., 1999; American Diabetes Association, 2008a). Furthermore, patients who 
have the under-listed additional risk factors should also undergo screening for 
diabetes (Rodbard et al., 2007; American Diabetes Association, 2008c; American 
Diabetes Association, 2008a): 
• Irregular physical activity. 
• A first or second degree relative with diabetes. 
• High-risk ethnic groups such as non-Hispanic blacks, Hispanic / Latino 
Americans, Asian Americans, Pacific Islanders, American Indians and Alaska 
Natives. 
• Women who had GDM or delivered a baby weighing > 9 lb.  
• Patients with low HDL cholesterol or high TG. 
• Clinical conditions associated with insulin resistance or signs of insulin 
resistance, example severe obesity, acanthosis nigricans, dyslipidaemia, 
hypertension, polycystic ovarian syndrome (PCOS). 
• People with IFG or IGT in a previous test. 
• History of CVD. 
• Age ≥ 45 years. 
Pre-diabetes detection is important and appropriate to prevent the progression of the 
pre-diabetes to diabetes and to decrease the risk of the disease complications 
(American Diabetes Association, 2008c). 
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2.6 Warning Signs and Symptoms of Diabetes 
 People with type 1 diabetes present with acute symptoms of diabetes and 
elevated blood glucose levels, so most cases are diagnosed directly after the onset of 
hyperglycaemia. On the other hand, type 2 diabetes is difficult to diagnose before the 
appearance of complications (American Diabetes Association, 2008a). Symptoms of 
extreme hyperglycaemia include: frequent urination; extreme hunger; unusual thirst; 
extreme fatigue; unusual weight loss; irritability; frequent infections; and blurred 
vision. Additionally, type 2 diabetic patients can experience: poor wound healing; 
tingling in the hands and feet; and repeated gum, skin, or bladder infections. 
Uncontrolled diabetes can cause acute life-threatening hyperglycaemia with 
ketoacidosis or non-ketotic hyperosmolar syndrome (World Health Organization 
Consultation, 1999; American Diabetes Association, 2008c; American Diabetes 
Association, 2008a).  
 
2.7 Prevalence of Diabetes Mellitus 
Diabetes mellitus is considered one of the most prevalent chronic diseases 
worldwide. The diabetes population is increasing steadily for numerous reasons, 
including population growth, aging, decreased physical activity, obesity, and 
urbanization (World Health Organization, 2000). Diabetes mellitus is recognized as 
one of the common non-communicable diseases worldwide, and is a major cause of 
mortality and morbidity (World Health Organization, 2000; Regional Committee, 
2008). The incidence of type 2 diabetes is steadily increasing in Europe and the U.S., 
and has rapidly increased in Africa, Asia, and South America, making this disease an 
epidemic of public health significance (World Health Organization, 2000; Boyle et 
al., 2001). Based on statistics from hospital data and routinely collected information; 
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Ministry of Health in Iraq show that non-communicable diseases represent the most 
leading cause of mortality (tenth leading cause) from five years old and over for the 
last past years (World Health Organization, 2006). They account for about 60% of 
deaths in Iraq (World Health Organization, 2006). 
 
In 1995, the World Health Organization (WHO) estimated that 135 million 
individuals were diabetic. This number is projected to increase to 300 million people 
by 2025, with 42% of this increase occurring in developed countries (King et al., 
1998). In 1998, the WHO predicted a three-fold increase in the prevalence of 
diabetes mellitus in Asia by 2025. This dramatic increase will be felt not only in the 
larger nations, i.e., China and India, but also in rapidly developing Asian nations like 
Singapore and Malaysia (King et al., 1998). The International Diabetes Federation 
(IDF) has estimated that the number of diabetic patients in 2003 and 2025 will be 
194 million and 333 million, respectively (Zimmet et al., 2003). Africans, Middle 
East populations, Asia, and Latin America had the highest rates of type 2 diabetes, 
with diabetics representing 98%, 97%, 91%, and 88%, respectively (Zimmet et al., 
2003).  
 
According to the IDF report estimation in 2006 about 246 million people 
worldwide were diabetic, and that number was expected to increase to 380 million 
diabetic within the next 20 years, and more than 70% of this increase will be in the 
developing countries (International Diabetes Federation, 2006).  Based on the 2006 
IDF estimations, diabetes affected 67 million people in the Western Pacific, 53 
million Europeans, 40.9 million people in India, and 39.8 million Chinese 
(International Diabetes Federation, 2006). High diabetes prevalence in 2007 were 
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reported in five countries which are Nauru (30.7%), United Arab 
Emirates (19.5%), Saudi Arabia (16.7%), Bahrain (15.2%), and Kuwait (14.4%) 
(International Diabetes Federation, 2006). 
 
The prevalence of diabetes in the U.S. is increasing (5.6 million in 1980, to 
6.6 million in 1990 and 8.1 million in 1994) (Centers for Disease Control and 
Prevention, 2008).  In 2007, the total prevalence of diagnosed and undiagnosed 
diabetes in American adults and children was 23.6 million, or 7.8% of the population 
(Centers for Disease Control and Prevention, 2007). The prevalence of diabetes in 
patients ≥ 20 years was 23.5 million, equal to 10.7% of the total population. Fifty-
seven million people were estimated to have pre-diabetes (Centers for Disease 
Control and Prevention, 2007). 
 
    The prevalence of diabetes mellitus in Malaysia has steadily increased over 
time. In 1960, 0.65% of Malaysians were estimated to have type 2 diabetes, but this 
number increased to 2% by 1982. According to the First National Health and 
Morbidity Survey (NHMS), the prevalence of diabetes mellitus in 1986 rose to 6.3% 
(Ministry of Health Malaysia, 1986). The Second NHMS, estimated that 8.3% of the 
Malaysian population had diabetes (Bakri, 2007). In 1993, another estimation for the 
diabetes prevalence in Malaysia showed that diabetes among adults was 8.2% in the 
urban areas and 6.7 % in the rural areas (World Health Organization, 2000). 
Furthermore, the Third NHMS, conducted between April and July 2006, estimated 
that 14.9% of the Malaysian population older than 30 years had diabetes. This shows 
that the diabetes prevalence in Malaysia has been increased much more than 
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expected by the IDF estimation which was 12.4% diabetes prevalence in 2025 
(International Diabetes Federation, 2003; Zanariah et al., 2008).  
 
The prevalence of diabetic complications remain high, 10% of diabetic 
patients had kidney disease, and 50% developed nerve damage after having diabetes 
for over 25 years (Bakri, 2007). Diabetic patients are 2-4 times more likely to 
develop heart disease and about 27.7 times more likely to require leg amputation due 
to diabetic neuropathy (Bakri, 2007).  In many Asian countries, stroke and renal 
disease are the most common causes of death among diabetic patients (World Health 
Organization, 2000).  About 15,000-39,000 diabetic patients loss their sight over the 
course of their lifetimes. Hospital data confirm the complication rates in many of the 
diabetic patients (Bakri, 2007). Ten to 20 percent of diabetic patients have 
hypertension, while 29% have hypercholesterolemia. The prevalence of undiagnosed 
diabetes in Malaysia is estimated to be around 2.5% (NHMS II) (Bakri, 2007). 
 
Diabetes mellitus is the 5th leading cause of death in most developed 
countries and the 7th leading cause of death in the U.S. (Centers for Disease Control 
and Prevention, 2007).  However, lower mortality rates were reported in the poorest 
countries: Mongolia, Chile, Paraguay, Iceland, and highest in North America, the 
Eastern Mediterranean and Middle East, Mauritius and in the small Western Pacific 
island countries (International Diabetes Federation, 2006). In Malaysia, the mortality 
rate of diabetes increased by 50% from 1991 to 2001 (Ooyub et al., 2004). Diabetes 
is considered the 6th most common cause of death in Singapore (Lee, 2000). 
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2.8 Economic Burden of Diabetes Mellitus 
Because of the severity and chronic nature of its complications, diabetes 
mellitus is a costly disease for both the diabetic patient and the healthcare sector. The 
costs of diabetes include: direct cost to the patients and their families, direct cost to 
the healthcare sector, indirect cost to society (productivity cost), and psychosocial 
cost (Zhang et al., 2003; Ooyub et al., 2004).  
 
In 2007, the estimated cost of caring for diabetic patients in the U.S. was 174 
billion dollars (American Diabetes Association, 2008b). Direct and indirect medical 
costs in the U.S. attributable to diabetes in 2002 were 132 billion dollar (Hogan et 
al., 2003).  In 2003, the total cost of screening 54.4 million Americans for diabetes 
was 3.03 - 5.3 billion dollars, with the direct medical costs totalling 2.16 - 3.76 
billion dollars. Pre-diabetes or undiagnosed diabetes cost 247 - 332 dollars per 
patient. While most screening strategies cost less than $200 per person, the best 
screening strategy, HbA1c, is also the most expensive (Zhang et al., 2003).  
 
In Australia, at least $720 million US were spent on diabetes healthcare in 
1995 (World Health Organization, 2000). In 2005 WHO used econometric models to 
estimate diabetes, heart disease, and stroke which together cost 557.7 billion dollar in 
lost national income in China between 2005 and 2015, 303.2 billion dollar in India, 
49.2 billion dollar; these are very large losses (International Diabetes Federation, 
2006).  
A Malaysian study in 2002 showed that the annual provider cost per diabetic 
patient was RM 185.97. However, the direct cost of each visit for one diabetic patient 
was RM 53.03 (Ooyub et al., 2004). The cost of providing annual care to a diabetic 
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patient was 2.4 times greater than that provided to a non–diabetic patient of the same 
age, gender, and geographical location (Selby et al., 1997). The primary care 
interventions for the chronic disease by public health policy are more costly than 
secondary and tertiary care interventions (Ramli and Taher, 2008). 
 
2.9 Management of Diabetes Mellitus According to the American Guidelines 
The appropriate components of care for diabetic patients include nutritional 
therapy, physical activity, weight management, pharmacological treatment, and self-
management education. The target laboratory values signifying sufficient glycaemic 
control are: HbA1c ≤ 6.5%; FPG < 110 mg/dl (or < 6.1 mmol/l); and a 2-hour 
postprandial glucose concentration < 140 mg/dl (or < 7.7 mmol/l) (Rodbard et al., 
2007). 
 
When a patient’s HbA1c is between 6-7%, the physician should prescribe 
single OHAs. Additional medication is considered if monotherapy does not achieve 
sufficient glycaemic control within 2 - 3 months (Rodbard et al., 2007). For an initial 
HbA1c between 7% - 8%, the patient should receive two anti-diabetic medications. If 
glycaemic control is not achieved within 2 - 3 months, the doses of the current 
medications can be increased, or additional medications can be added (Rodbard et 
al., 2007). Metformin is recommended by the ADA as a first line oral anti-diabetic 
medication (American Diabetes Association, 2008c). Insulin therapy, either as a 
monotherapy or in combination with oral anti-diabetic agents, is considered when the 
patient’s HbA1c levels are between 8% - 10%. At HbA1c levels greater than 10%, 
intense insulin therapy is strongly recommended (Rodbard et al., 2007).  
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2.10 Management of Diabetes Mellitus According to the Malaysian Clinical 
Practice Guidelines 
Diabetes management includes non-pharmacological and pharmacological 
therapies. Sufficient glycaemic control is considered achieved when the FPG level is 
between 4.4 – 6.1 mmol/l, and/or random plasma glucose is between 4.4 – 8 mmol/l, 
and/or the HbA1c level is less than 6.5% (Ministry of Health Malaysia et al., 2004).  
 
2.10.1     Non-pharmacologic Management 
Non pharmacological management of diabetes mellitus include diabetes 
education and lifestyle modifications. The latter includes: 
 
• Diet Therapy:  
Dietary management is an essential part of any diabetes management strategy. 
Even with medication, effective management of diabetes cannot be achieved 
without the proper diet (Franz, 1997; Ministry of Health Malaysia et al., 2004). 
 
• Physical Activity: 
Any increase in physical activity benefits diabetes management (Franz, 1997; 
Ministry of Health Malaysia et al., 2004). Physical activity prevents and helps 
in the treatment of many established atherosclerotic risk factors, like high BP, 
insulin resistance and glucose intolerance, high TG levels, low HDL cholesterol 
and obesity. Exercise in addition to the weight loss can decrease LDL 
cholesterol and limit the reduction in HDL cholesterol (Stefanick et al., 1998). 
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2.10.2 Pharmacologic Therapy 
 
2.10.2(a)  Oral Agent Monotherapy 
If a newly diagnosed diabetic patient does not achieve sufficient glycaemic 
control within 1 – 3 months of the lifestyle modification, oral anti-diabetic agents 
(see section 2.11) should be started.  Alternatively, oral anti-diabetic agents can be 
started in addition to lifestyle modifications in the type 2 diabetic patients, especially 
in those who present with complications (Ministry of Health Malaysia et al., 2004). 
 
2.10.2(b)   Combinations of Oral Agents 
Furthermore, if the patient does not reach the target glycaemic control within 
3 months of a single medication, or if the HbA1c is greater than 10% upon diagnosis, 
multiple OHAs should be prescribed (Ministry of Health Malaysia et al., 2004). 
 
2.10.2(c)   Combinations of OHAs and Insulin  
If optimal doses of the maximal combination therapy do not achieve 
glycaemic control within 3 months, adding intermediate- or long - acting insulin is 
recommended. The combination of insulin and oral anti-diabetic agents has been 
shown to dramatically improve glycaemic control (Ministry of Health Malaysia et 
al., 2004). Insulin can be combined with the following OHAs for patients with 
uncontrolled or severe type 2 diabetes: 
• Biguanides (metformin). 
• Insulin secretagogues: SU. 
• Insulin sensitizers or TZD (the combination of a TZD and insulin is not an 
approved indication). 
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• α-glucosidase inhibitor, e.g., acarbose. 
Insulin dose can be increased until the target FPG level is achieved (Ministry of 
Health Malaysia et al., 2004). 
 
2.10.2(d)   Insulin Therapy  
  Insulin is a 51-amino acid peptide hormone first identified in 1921; it is 
synthesized and secreted by pancreatic beta cells (Wilcox, 2005). The first artificial 
insulin preparations come from cows and then from pigs; later in the early 1980s the 
human insulin produced using the Recombinant DNA technology (Vajo et al., 2001). 
The use of insulin as anti-diabetic medication as reported in a study had no 
association with the mortality adjusted hazard ratio in comparing with other anti 
diabetic medications (Masoudi et al., 2005). while another study suggested an 
increase in the mortality rate with insulin treatment (Murcia et al., 2004).  
 
• Rapid Acting Insulin  
 Insulin lispro and insulin aspart, both of which are rapidly absorbed, 
are suitable at mealtime (Dewitt and Hirsch, 2003). 
• Short  Acting Insulin  
   Regular insulin has a delayed onset of action of 30–60 min, and is 
therefore given 20-30 minutes prior to meals (Dewitt and Hirsch, 2003).  
• Intermediate Acting Insulin 
   Neutral protamine hagedorn (NPH) is an isophene insulin, and thus is 
absorbed slowly (Dewitt and Hirsch, 2003). 
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• Long Acting Insulin  
   Ultralente insulin, which is a zinc-extended insulin, is released slowly, 
peaking at 20 to 24 hours (Dewitt and Hirsch, 2003).  
 
2.10.2(d).1.   Short-Term Use 
Emergencies, stress, surgery, pregnancy, breast-feeding, acute illnesses, or 
any situation causing marked hyperglycaemia and severe metabolic decompensation 
(i.e., hyperosmolar non-ketotic coma, lactic acidosis, diabetic ketoacidosis, severe 
hypertriglyceridaemia) can necessitate the use of insulin as an initial therapy in type 
2 diabetic patients (Ministry of Health Malaysia et al., 2004). 
 
2.10.2(d).2.   Long-Term Use 
If a patient receiving an optimal dose of combination therapy or insulin does 
not achieve sufficient glycaemic control, changing to a multi-dose insulin regimen 
can be considered. In this case, the patient would stop insulin secretagogues, but 
could continue taking insulin sensitizers like metformin and TZD (Ministry of Health 
Malaysia et al., 2004). 
 
2.11 Oral Anti-Diabetic Agents  
There are five classes of oral anti-diabetic agents (Kimmel and Inzucchi, 
2005; Joshi and Joshi, 2009). The first four classes are mentioned previously in 
(section 2.10.2.C.) and fifth class is insulin secretagogues – non-sulphonylureas (e.g., 
repaglinide, nateglinide). Recently, dipeptidyl peptidase-4 inhibitors (DPP–IV) and 
glucagon-like peptide-1 (GLP1) agents were registered for use in the U.S. and 
Europe (Joshi and Joshi, 2009). 
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2.11.1  Biguanides (Metformin) 
Metformin is widely accepted as the first-line drug when instituting 
monotherapy. It is effective, safe, cheap, and is the only anti–diabetic drug to 
promote weight loss (Heine et al., 2006; Joshi and Joshi, 2009). In trials versus a 
placebo, metformin was shown to reduce HbA1c by 1-2% and LDL cholesterol and 
TG by 0.12 - 0.26 mmol/L. Metformin had little effect on HDL cholesterol levels. 
UKPDS and other more recent trials demonstrated that metformin reduces diabetes-
related death and diabetes related clinical end-points in diabetic patients more than 
patients receiving insulin and/or sulfonylurea (Uk Prospective Diabetes Study 
(Ukpds) Group, 1998a; Holman et al., 2008). A Japanese study indicated that 
metformin had a potent anti–atherogenic effect in patients with type 2 diabetes 
(Katakami et al., 2004). The prevalence of heart failure in patients using metformin 
is unknown, although published data suggest an incidence between 10 - 25% of 
patients receiving metformin (Kimmel and Inzucchi, 2005; Eurich et al., 2007). 
Metformin is also associated with a lower rate of hospital admission compared to 
other anti-diabetic drugs. Metformin is approved as a monotherapy and can be used 
in combination with other oral anti-diabetic agents and/or insulin (Eurich et al., 
2007). The Diabetes Prevention Program data showed that in patients with IGT, use 
of metformin reduced the risk of diabetes progression over patients who made only 
lifestyle changes (31% versus 58%, respectively) (Diabetes Prevention Program 
Research, 2002). 
 
2.11.2  Insulin Secretagogues – Sulfonylurea 
 SU are classified as either first or second generation, depending on their 
duration of action. Examples of the second generation SU group are glibenclamide, 
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gliclazide, and glipizide. Most of the clinical trials reported that SUs reduce HbA1c 
by 1.5 – 2% when used as monotherapy (Joshi and Joshi, 2009). Like metformin, 
these drugs are effective both as monotherapy and in combination with other anti-
diabetic agents. There are no new data from prospective clinical trials on its vascular 
endpoints. Some retrospective analyses have even reported worse cardiovascular 
outcomes in patients taking SU agents compared to those taking metformin or TZD 
(Uk Prospective Diabetes Study (Ukpds) Group, 1998b; Johnson et al., 2002). 
However, a recent meta-analysis indicated that SU are not associated with 
cardiovascular events (Heine et al., 2006). Further complicating the issue, one study 
found that SU as monotherapy was associated with a worse outcome (all-cause 
mortality and all-cause hospitalization) (Eurich et al., 2005), although another study 
refuted this association (Masoudi et al., 2005). A Japanese study found that 
gliclazide, but not glibenclamide, had a potent anti-atherogenic effect in type 2 
diabetic patients (Katakami et al., 2004).  
 
2.11.3  Insulin Secretagogues – Non-Sulfonylureas 
 Also known as glinides, non-sulfonylureas have different efficacies. This 
class of drugs includes repaglinide and nateglanide. Both drugs are approved as 
monotherapy and in combination with most other oral agents. Unlike SUs, these 
drugs can be used in patients with sulpha allergies.  Unfortunately, these drugs have 
shorter half–lives and are more expensive than SU (Joshi and Joshi, 2009). Long-
term outcomes data are unavailable; however, their effect on long term complication 
rates is likely to be similar to SU (Kimmel and Inzucchi, 2005). 
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